Literature DB >> 1714518

Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells.

F Shang1, H Huang, K Revesz, H C Chen, R Herz, A Pinter.   

Abstract

Eight monoclonal antibodies reactive with the matrix protein of human immunodeficiency virus type 1 (HIV-1), p17gag, were isolated from rats which had been immunized with solubilized HIV-1 lysate. The epitope specificities of these antibodies were determined with a series of synthetic peptides representing overlapping regions of p17. Six of the antibodies were mapped to three distinct regions of p17, while two antibodies (G11g1 and G11h3) reacted only with intact recombinant p17, suggesting that they were directed against conformational or discontinuous epitopes. All the antibodies bound to HIV-infected cells which had been permeabilized with acetone, but only G11g1 and G11h3 reacted with live HIV-infected cells. Specificity studies with diverse virus strains demonstrated that these two antibodies recognized distinct epitopes, one which was group specific for HIV-1, and one which was shared with HIV type 2 and simian immunodeficiency virus. Binding competition studies indicated that these epitopes were proximal in native p17. Despite their reactivity with intact cells, these two antibodies did not possess appreciable virus-neutralizing activity. These results indicate that a form of p17 is expressed on the surfaces of live HIV-infected cells which is accessible to some, but not all, antibodies against p17. These cell surface molecules may play a role in the generation of antibodies against p17gag that are characteristic of early stages of HIV infection, and they may act as natural targets for the immune system and as potential targets for immunotherapy of HIV-infected cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714518      PMCID: PMC248937     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Monoclonal antibody to the amino-terminal L sequence of murine leukemia virus glycosylated gag polyproteins demonstrates their unusual orientation in the cell membrane.

Authors:  E A Pillemer; D A Kooistra; O N Witte; I L Weissman
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

2.  Analysis of the secondary structure of the human immunodeficiency virus (HIV) proteins p17, gp120, and gp41 by computer modeling based on neural network methods.

Authors:  H Andreassen; H Bohr; J Bohr; S Brunak; T Bugge; R M Cotterill; C Jacobsen; P Kusk; B Lautrup; S B Petersen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

3.  Myristoylation of gag proteins of HIV-1 plays an important role in virus assembly.

Authors:  R Pal; M S Reitz; E Tschachler; R C Gallo; M G Sarngadharan; F D Veronese
Journal:  AIDS Res Hum Retroviruses       Date:  1990-06       Impact factor: 2.205

4.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

5.  Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1.

Authors:  A Pinter; W J Honnen; S A Tilley; C Bona; H Zaghouani; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

6.  Epitope mapping of the HIV-1 gag region with monoclonal antibodies.

Authors:  J Hinkula; J Rosen; V A Sundqvist; T Stigbrand; B Wahren
Journal:  Mol Immunol       Date:  1990-05       Impact factor: 4.407

7.  Characterization of monoclonal antibodies against the p17 core protein of the human immunodeficiency virus 1.

Authors:  J Cogniaux; N De Schepper; M L Blondiau; B Cornet; P Horal; A Vahlne
Journal:  J Immunol Methods       Date:  1990-04-17       Impact factor: 2.303

8.  HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.

Authors:  A Achour; O Picard; D Zagury; P S Sarin; R C Gallo; P H Naylor; A L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

9.  Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.

Authors:  W E Robinson; T Kawamura; M K Gorny; D Lake; J Y Xu; Y Matsumoto; T Sugano; Y Masuho; W M Mitchell; E Hersh
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

10.  Lack of reactivity of anti-human immunodeficiency virus (HIV) P17/18 antibodies against alpha 1 thymosin and of anti-alpha 1 thymosin monoclonal antibody against P17/18 protein.

Authors:  J Ritter; M Sepetjan; J C Monier
Journal:  Immunol Lett       Date:  1987-11       Impact factor: 3.685

View more
  16 in total

Review 1.  Uses of flow cytometry in virology.

Authors:  J J McSharry
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

2.  A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE.

Authors:  E Buratti; S G Tisminetzky; P D'Agaro; F E Baralle
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus.

Authors:  S H Pincus; R Cole; R Ireland; F McAtee; R Fujisawa; J Portis
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

4.  Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.

Authors:  S Vijh-Warrier; A Pinter; W J Honnen; S A Tilley
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses.

Authors:  A Corbin; A C Prats; J L Darlix; M Sitbon
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

6.  The human immunodeficiency virus (HIV) gag gene product p18 is responsible for enhanced fusogenicity and host range tropism of the highly cytopathic HIV-1-NDK strain.

Authors:  J de Mareuil; B Brichacek; D Salaun; J C Chermann; I Hirsch
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

Review 7.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

8.  Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene.

Authors:  M Miyazawa; J Nishio; B Chesebro
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

9.  Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly.

Authors:  P Spearman; J J Wang; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.

Authors:  Hongtao Zhang; Raja Fayad; Xilin Wang; Daniel Quinn; Liang Qiao
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.